Open AccessIncreased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature
Author(s) -
Patriquin Christopher,
Leber Brian
Publication year - 2015
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.161
Subject(s) - paroxysmal nocturnal hemoglobinuria , eculizumab , medicine , hemoglobinuria , pregnancy , pediatrics , intensive care medicine , anemia , immunology , antibody , complement system , genetics , biology
Key Clinical Message Paroxysmal nocturnal hemoglobinuria ( PNH ) results from reduced complement regulatory proteins on hematopoietic cells, predisposing patients to intravascular hemolysis, thrombophilia, and cytopenias. Women diagnosed in pregnancy can experience significant maternofetal complications. Trials of eculizumab in PNH excluded pregnant women. Here, we report the first Canadian patient taken through pregnancy on eculizumab.